Product
GLP1-RA
2 clinical trials
25 indications
Indication
HypopituitarismIndication
Diabetes InsipidusIndication
Pancreatogenic diabetesIndication
Mental Health DisorderIndication
LonelinessIndication
Hypothalamic DiseasesIndication
Pituitary DisordersIndication
OxytocinIndication
ObesityIndication
Liver DiseaseIndication
Fibrosis of the LiverIndication
Fatty LiverIndication
NAFLDIndication
Unintentional Weight LossIndication
Insulin ResistanceIndication
Insulin SensitivityIndication
Insulin Sensitivity/ResistanceIndication
Metabolic DiseasesIndication
DiabetesIndication
Diabetes MellitusIndication
Type 2Indication
Nonalcoholic SteatohepatitisIndication
Nonalcoholic Fatty Liver DiseaseIndication
Nonalcoholic Fatty LiverIndication
Non-alcoholic SteatohepatitisClinical trial
Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Placebo-controlled, Proof-of-concept, Physiopathological Study (GLP1 Study)Status: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
Endoscopic Sleeve Gastroplasty (ESG) Versus Glucagon-like Peptide 1 Receptor Agonist (GLP-1RA) Versus ESG + GLP-1RA in Patients With Obesity, Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis: A Randomized Controlled TrialStatus: Not yet recruiting, Estimated PCD: 2025-07-01